Jeffrey L Cummings (Cleveland Clinic Lou Ruvo Center for Brain Health, Las Vegas, NV), a valued member of our editorial board for US Neurology, discusses how disease-modification is being approached for Alzheimer’s disease and the important emerging role of monoclonal antibodies, which are being used to target various biological targets in Alzheimer’s in clinical trials.
1. How is disease-modification being approached for Alzheimer’s disease (AD)? (0:12)
2. What role do monocloncal antibodies have in the treatment of AD? (0:43)
3. When in the course of AD should monocloncal antibodies be used? (1:32)
4. What are the biological targets of monocloncal antibodies? (2:47)
5. What are some of the promising monocloncal antibodies in trials now? (3:30)
6. What are the major challenges to developing monocloncal antibodies? (4:19)
Speaker disclosure: Jeffrey L Cummings has provided consultation to the following pharmaceutical companies: Acadia, Accera, Actinogen, ADAMAS, Alkahest, Allergan, Alzheon, Avanir, Axovant, Axsome, BiOasis Technologies, Biogen, Eisai, Genentech, Grifols, Kyowa, Lilly, Lundbeck, Merck, Nutricia, Otsuka, QR Pharma, Resverlogix, Roche, Samus, Servier, Suven, Takeda, Toyoma, and United Neuroscience companies. Dr Cummings has provided consultation to Neurocog, MedAvante, and Bracket assessment companies, as well as the Global Alzheimer Platform (GAP) foundation. Dr Cummings owns stocks in Cummings owns stocks in ADAMAS, Alzheon, BioAsis, EIP Pharma, Prana, Sonexa, MedAvante, Neurotrax, and QR Pharma. Dr Cummings owns the copyright of the Neuropsychiatric Inventory, and receives research support from Avid and Teva. NIH support: COBRE grant# P20GM109025; TRC-PAD # R01AG053798; DIAGNOSE CTE # U01NS093334.
Filmed during a video call with Jeffrey L Cummings from his office at the Cleveland Clinic Lou Ruvo Center for Brain Health, Las Vegas, NV, US, May 2018.
Share this Video
Related Videos In Alzheimer's Disease & Dementia
Michael Weiner, AD/PD 2021: The Alzheimer’s Disease Neuroimaging Initiative (ADNI)
It was a great pleasure to meet with Michael Weiner (University of California, San Francisco, CA, USA), the Principal Investigator for the Alzheimer’s Disease Neuroimaging Initiative (ADNI), to discuss the initiative’s aims, design and future developments. The abstract entitled ‘Validating Plasma Tests for Amyloid, Tau, and Neurodegeneration Using the Alzheimer’s Disease Neuroimaging Initiative (ADNI)’ was […]
Marwan Sabbagh, AD/PD 2021: Phase 2 MCLENA-1 Trial
TouchNEUROLOGY had the great pleasure of speaking with Marwan Sabbagh (Cleveland Clinic Lerner College of Medicine, Cleveland, OH, USA) to discuss the phase 2 MCLENA-1 clinical trial rationale, assessing lenalidomide in patients with mild cognitive impairment due to Alzheimer’s Disease. The abstract entitled ‘Rationale for the MCLENA-1: A Phase II Clinical Trial for the Assessment […]
Yona Levites, AD/PD 2021: Immunotherapeutic Approaches in Alzheimer’s Disease (Part 1)
We had the pleasure of meeting with Yona Levites (Center for Translational Research in Neurodegenerative Disease, University of Florida, Gainesville, FL, USA) to discuss immunotherapeutic approaches in Alzheimer’s Disease. Part 2 of the discussion can be viewed here. The abstract entitled ‘Immunotherapeutic approaches in Alzheimer’s Disease’ was presented at The 15th International Conference for Alzheimer’s […]
Journal articles and more to your inbox
Get the latest clinical insights from touchNEUROLOGYSign me up!